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Background: Most patients with diabetes also have hypertension, a cardiovascular risk factor associated with endothelial cell (EC) dysfunction 
and loss of nitric oxide (NO) bioavailability. Recent studies have shown that dipeptidyl peptidase-4 (DPP4) inhibition reduces blood pressure (BP) 
in patients with diabetes, although the underlying mechanism is not understood. In this study, we examined the hypothesis that EC dysfunction 
and elevated BP in hypertensive rats are reversed with a DPP4 inhibitor (saxagliptin) due to direct effects on NO synthase (eNOS) activity and 
inflammation.
Methods: Spontaneously hypertensive (SH) rats were treated with vehicle or saxagliptin (10 mg/kg/day) for 8 weeks. Nitric oxide (NO) and 
peroxynitrite (ONOO-) release were measured ex vivo in aortic and glomerular ECs using an electrochemical nanosensor array following stimulation 
with calcium ionophore. Changes in EC function were correlated with fasting glucose, blood pressure and sICAM-1 levels.
Results: Saxagliptin treatment increased aortic and glomerular NO release by 22% (287 ± 28 to 350 ± 22 nM, p<0.001) and 23% (89 ± 10 
to 109 ± 7 nM, p<0.001), respectively, with comparable reductions in ONOO- levels; the NO/ONOO- ratio increased by >50% in both EC types 
(p<0.001) as compared to vehicle. Despite normal fasting glucose levels in these animals, saxagliptin treatment reduced mean arterial pressure by 
12 mmHg (p<0.001) and decreased sICAM-1 levels by 37% (p<0.01).
Conclusion: The results of this study suggest that DPP4 inhibition reduces BP and inflammation in hypertensive rats by increasing eNOS coupling 
and NO bioavailability, independent of changes in fasting glucose.
